Richard de Boer

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

Scott N. Holden, Sabine Eckhardt, R. Basser et al. · Annals of Oncology · 2005 · 306 citations · Full text

Medicine, Pharmacology, Pathology +6

Premature and accelerated aging: HIV or HAART?

Reuben L. Smith, Richard de Boer, Stanley Brul et al. · Frontiers in Genetics · 2013 · 131 citations · Full text

Aging, Immunology, Biogerontology +17

Improved detection of microbial DNA after bead-beating before DNA isolation

Richard de Boer, Remco P. H. Peters, Sonja Gierveld et al. · Journal of Microbiological Methods · 2009 · 126 citations

Pathogen Detection, Dna Analysis, Dna Replication +5

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial

Ian Smith, Denise A. Yardley, Howard A. Burris et al. · Journal of Clinical Oncology · 2017 · 120 citations

Breast Oncology, Gynecology, Pharmacotherapy +16

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide

Jim Siderov, Pratibha Prasad, Richard de Boer et al. · British Journal of Cancer · 2002 · 64 citations · Full text

Allergy, Intravenous Etoposide, Medicine +4